Movement Alert｜ResMed Falls 7.69% in Regular Trading, Earnings Beat Estimates but Revenue Growth Slowdown Triggers Multiple Downgrades

Market Focus08-07

On August 7, ResMed declined 7.69% in regular trading, trading at approximately $203.76 per share, with turnover of $76.64 million.

The decline was triggered by the company's fiscal Q4 earnings release and subsequent analyst downgrades. ResMed reported adjusted EPS of $2.95, beating the $2.89 consensus, while revenue of $1.46 billion matched expectations with 8.1% year-over-year growth. However, the revenue growth rate has decelerated from prior double-digit levels to approximately 8%, forming a notable gap with the company's three-year EPS CAGR of 19%.

Morgan Stanley downgraded the stock to equal weight from overweight, warning that GLP-1 weight-loss drugs and competitive product entries will structurally compress growth. RBC Capital and Citi also reduced ratings or price targets. Additionally, Astral field safety notification costs of approximately $41.9 million pressured GAAP margins. While the company announced plans to return over $1.85 billion to shareholders in FY2027 and raised its quarterly dividend 10% to $0.66 per share, these measures failed to offset bearish sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153457750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153457750","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ResMed Falls 7.69% in Regular Trading, Earnings Beat Estimates but Revenue Growth Slowdown Triggers Multiple Downgrades","media":"Market Focus","content":"<p><p>On August 7, ResMed declined 7.69% in regular trading, trading at approximately $203.76 per share, with turnover of $76.64 million.</p><p>The decline was triggered by the company's fiscal Q4 earnings release and subsequent analyst downgrades. ResMed reported adjusted EPS of $2.95, beating the $2.89 consensus, while revenue of $1.46 billion matched expectations with 8.1% year-over-year growth. However, the revenue growth rate has decelerated from prior double-digit levels to approximately 8%, forming a notable gap with the company's three-year EPS CAGR of 19%.</p><p>Morgan Stanley downgraded the stock to equal weight from overweight, warning that GLP-1 weight-loss drugs and competitive product entries will structurally compress growth. RBC Capital and Citi also reduced ratings or price targets. Additionally, Astral field safety notification costs of approximately $41.9 million pressured GAAP margins. While the company announced plans to return over $1.85 billion to shareholders in FY2027 and raised its quarterly dividend 10% to $0.66 per share, these measures failed to offset bearish sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ResMed Falls 7.69% in Regular Trading, Earnings Beat Estimates but Revenue Growth Slowdown Triggers Multiple Downgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ResMed Falls 7.69% in Regular Trading, Earnings Beat Estimates but Revenue Growth Slowdown Triggers Multiple Downgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, ResMed declined 7.69% in regular trading, trading at approximately $203.76 per share, with turnover of $76.64 million.</p><p>The decline was triggered by the company's fiscal Q4 earnings release and subsequent analyst downgrades. ResMed reported adjusted EPS of $2.95, beating the $2.89 consensus, while revenue of $1.46 billion matched expectations with 8.1% year-over-year growth. However, the revenue growth rate has decelerated from prior double-digit levels to approximately 8%, forming a notable gap with the company's three-year EPS CAGR of 19%.</p><p>Morgan Stanley downgraded the stock to equal weight from overweight, warning that GLP-1 weight-loss drugs and competitive product entries will structurally compress growth. RBC Capital and Citi also reduced ratings or price targets. Additionally, Astral field safety notification costs of approximately $41.9 million pressured GAAP margins. While the company announced plans to return over $1.85 billion to shareholders in FY2027 and raised its quarterly dividend 10% to $0.66 per share, these measures failed to offset bearish sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"","article_id":"1153457750","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153457750","pubTimestamp":1786110128,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, ResMed declined 7.69% in regular trading, trading at approximately $203.76 per share, with turnover of $76.64 million.The decline was triggered by the company's fiscal Q4 earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈"},"translate_title":"走势警报|瑞思迈常规交易下跌7.69%，盈利超出预期，但收入增长放缓引发多次下调评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1},"content_text":"On August 7, ResMed declined 7.69% in regular trading, trading at approximately $203.76 per share, with turnover of $76.64 million.The decline was triggered by the company's fiscal Q4 earnings release and subsequent analyst downgrades. ResMed reported adjusted EPS of $2.95, beating the $2.89 consensus, while revenue of $1.46 billion matched expectations with 8.1% year-over-year growth. However, the revenue growth rate has decelerated from prior double-digit levels to approximately 8%, forming a notable gap with the company's three-year EPS CAGR of 19%.Morgan Stanley downgraded the stock to equal weight from overweight, warning that GLP-1 weight-loss drugs and competitive product entries will structurally compress growth. RBC Capital and Citi also reduced ratings or price targets. Additionally, Astral field safety notification costs of approximately $41.9 million pressured GAAP margins. While the company announced plans to return over $1.85 billion to shareholders in FY2027 and raised its quarterly dividend 10% to $0.66 per share, these measures failed to offset bearish sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153457750","isCrawlerRequest":true}